期刊文献+

固相萃取高效液相色谱法测定左乙拉西坦血药浓度 被引量:10

Determination of levetiracetam in serum by solid phase extraction and high performance liquid chromatography
原文传递
导出
摘要 目的建立高效液相色谱测定血清中左乙拉西坦(抗癫痫病)浓度的方法。方法用Hypersil C18色谱柱,流动相为乙腈-水(6∶94),流速为0.8 mL.min-1,检测波长210 nm。血清样品上SPE柱,以含20%乙腈溶液作洗脱液,收集洗脱液直接进样测定。结果左乙拉西坦血清样品线性范围为0.7~100.0mg.L-1,8.93,35.71,71.42 mg.L-13种浓度方法回收率分别为102.6%,95.7%,98.1%,日内、日间RSD均小于7.5%。结论本方法准确性好、灵敏度高、操作简便,可满足左乙拉西坦血药浓度监测和药代动力学研究的要求。 Objective To establish a HPLC method for determination of the concentration of levetiracetam in serum.MethodsThe analysis was conducted with Hypersil C18 column.Acetonitrile-water was served as mobile phase,the flow number was 0.8 mL·min-1,and the detecting wavelength was at 210 nm.Serum sample was applied to SPE column.ResultsThe linear range of levetiracetam in serum was 0.7-100.0 mg·L-1.The recovery rate of low concentration,moderate concentration and high concentration(8.93,35.71,71.42 mg·L-1) was 102.6%、95.7%、98.1%,respectively.Both of the intra-day and inter-day RSD were less than 7.5%.ConclusionThis method is accurate,sensitive and simple.And it is suitable for the determination of the concentration of levetiracetam in serum and the pharmacokinetic study of levetiracetam.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第4期289-291,共3页 The Chinese Journal of Clinical Pharmacology
关键词 左乙拉西坦 固相萃取 高效液相色谱法 levetiracetam SPE HPLC
  • 相关文献

参考文献7

二级参考文献34

  • 1罗湘冀.左乙拉西坦的合成[J].药学进展,2004,28(9):413-417. 被引量:11
  • 2黄铁栓,朱金兰,李冰,胡雁,廖建湘.抗癫痫药物加重儿童癫痫发作的临床研究[J].中国当代儿科杂志,2004,6(5):401-402. 被引量:8
  • 3吴洁,鲍克容,许燮萍,汪梅先.经药物治疗的癫痫在学儿童的学习前景:500例调查分析[J].中国当代儿科杂志,1999,1(1):25-26. 被引量:2
  • 4吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 5Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy [ J ]. Pediatr Neurol, 2007, 36(4):227-230.
  • 6Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, et al. Oxcarbazepine monotherapy in children and adolescents: A single-center clinical experience [ J ]. Pediatr Neurol, 2006, 35(4) :235-239.
  • 7Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC, et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents [ J]. J Child Neurol, 2007, 22 (6) : 693 -699.
  • 8Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy [ J ]. Epilepsy Behav, 2007, 10 ( 1 ) : 105- 110.
  • 9Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambreehts D, et al. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center [ J]. Epilepsy Behav, 2007, 10(2) :296-303.
  • 10De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug[ J]. CNS Drug Rev, 2007, 13(1) :57-78.

共引文献63

同被引文献83

引证文献10

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部